We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04469530
Title Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903)
Acronym AflacST1903
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications
Therapies
Age Groups: child | adult
Covered Countries USA

Facility Status City State Zip Country Details
Aflac Cancer & Blood Disorders Centers RECRUITING Atlanta Georgia 30322 United States Details
Children's Healthcare of Atlanta RECRUITING Atlanta Georgia 30322 United States Details
Washington University School of Medicine RECRUITING Saint Louis Missouri 63110 United States Details
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC) RECRUITING Pittsburgh Pennsylvania 15224 United States Details
Texas Children's Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field